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Objectives. The aim of this study was to evaluate clinical and US-PD parameters in PsA during adalimumab treatment. Methods.A
retrospective study has been conducted in forty patients aﬀected by moderate-to-severe peripheral PsA. Clinical, laboratory, and
US-PD evaluations were performed at baseline, after 4, 12, and 24 weeks of treatment. They included erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), visual analogue scale (VAS), Health Assessment Questionnaire (HAQ) modiﬁed for
Spondyloarthritis,PsoriasisAreaSeverityIndex(PASI)score,the28-jointDiseaseActivityScore(DAS28),andUS-PDassessment.
US-PD ﬁndings were scored according to a semiquantitative scale (ranging 0–3) for synovial proliferation (SP), joint eﬀusion
(SE), bone erosions (BE), and PD. Results. Data obtained for clinical, laboratory ﬁndings and US-PD evaluation showed statistical
signiﬁcant improvement in all the measures performed except for BE. A signiﬁcant parallel decrease in SE, SP, and PD values were
demonstrated. Conclusion. This study demonstrated that US-PD is a valid technique in monitoring the response to adalimumab
in moderate-to-severe PsA.
1.Introduction
Psoriatic arthritis (PsA) is an inﬂammatory arthritis that
occurs in up to one-third of patients with psoriasis and is
usually diagnosed years after the appearance of cutaneous
psoriasis [1]. Joint involvement in these patients is a
potentially debilitating disease that may aﬀect enthesis, small
and large joints, and axial skeleton [2]. In particular, more
than half of the patients exhibit progressive erosive arthritis,
associated with severe functional impairment [3].
Despite clinical improvement with current disease mod-
ifying antirheumatic drugs (DMARDs), PsA results in radio-
logical damage in up to 47% of patients at a median interval
of 2 years [4]. Overexpression of tumor necrosis factor-α
(TNFα) is believed to play a key role in the pathogenic
mechanisms linking psoriasis and arthritis [5]. Similar to
rheumatoid arthritis (RA), several trials in PsA have shown
excellent clinical results with anti-TNFα agents such as
etanercept [6, 7], inﬂiximab [8], and adalimumab [9, 10].
Adalimumab is a recombinant, fully human monoclonal
antibody (IgG1) that binds with high aﬃnity and speciﬁcity
to TNF-α. This process of neutralization of TNF-α by a
speciﬁc monoclonal antibody should improve both skin and
joint manifestations of PsA [11].
The development of new devices for assessing activity of
articular involvement in PsA is a relevant topic of research
in rheumatology and more recently in dermatology. Among
these equipment, ultrasonography (US) is one of the most
interesting tool. Iagnocco et al. demonstrated the eﬃcacy
of adalimumab treatment not only in terms of clinical and
laboratory remission but also in terms of US parameters
in patients with RA [12]. Moreover, a study conducted
by Fiocco et al. evaluated the therapeutical response to
etanercept by the US assessment of rheumatoid and psoriatic
knee synovitis [13]. In fact, ultrasonography is a routinely
available and noninvasive technique to evaluate bone, car-
tilage, tendons, ligaments, and surrounding soft tissue and
relatively inexpensive bedside imaging modality with high2 Clinical and Developmental Immunology
patient acceptability. Furthermore, it allows the scanning of
all peripheral joints as many times as required in monitoring
early and active PsA [14].
This method allows the assessment in psoriatic joint
of both inﬂammation-related changes such as synovitis,
tenosynovitis, enthesitis, and bursitis and structural damage
such as cortical bone erosions. The application of power
Doppler (PD) can estimate the increase in synovium, tendon
sheaths, bursae, and enthesis perfusion due to a disorganized
pattern of blood vessels formation that is typical of PsA [15].
The aim of this study was to evaluate the use of US and
PD (US-PD) technique in monitoring joint involvement in
moderate-to-severe PsA patients treated with adalimumab
and to conﬁrm the presence of an association between US
and clinical and serological ﬁndings.
2.MaterialsandMethods
From January 2008 to December 2009, a retrospective study
has been conducted in our collaborative outpatients unit of
Dermatology and Rheumatology at the University of Rome
“Tor Vergata.” Forty patients (21 males and 19 females),
agedbetween33and76years,aﬀectedbymoderate-to-severe
peripheral PsA with cutaneous manifestation of psoriasis
were studied. Clinical diagnosis was made using CASPAR
(ClASsiﬁcation criteria for Psoriatic ARthritis) criteria for
PsA [14]. Patients underwent treatment with adalimumab
if they were unresponsive to or had contraindications
for at least two other conventional systemic treatments
(methotrexate, ciclosporin, leﬂunomide, sulphasalazine). All
patients were screened by chest radiography, laboratory tests
(including screening for hepatitis A, B, and C viruses),
and PPD skin test. Prior to treatment, all patients signed
written informed consent. Adalimumab was administrated
with a dose of 40mg subcutaneously, every other week.
Clinical, laboratory, and US-PD evaluations were performed
at baseline (T0), after 4 (T4), 12 (T12), and 24 (T24)
weeks of treatment. They included a general physical
examination, erythrocyte sedimentation rate (ESR), and C-
reactive protein (CRP) with normal range of 0–15mm/h and
0–0.5mg/dL, respectively. Disease activity assessment was
made using visual analogue scale (VAS), Health Assessment
Questionnaire modiﬁed for Spondyloarthritis (SpA-HAQ),
Psoriasis Area Severity Index score (PASI), the 28-joint
Disease Activity Score (DAS28-ESR), and US-PD.
Patients’ demographics and clinicolaboratory charac-
teristics as well as previously performed treatments are
summarized in Table 1.
At baseline, patients’ evaluations were performed by a
dermatologist and a rheumatologist for both cutaneous and
joint disease.
The joint considered by the physician as the most
involved by arthritis was evaluated. The selected joint,
the same for each patient, was scanned by US-PD: 10
metatarsophalangeal (3 II ﬁnger and 7 toe right and left), 18
metacarpophalangeal (8 II ﬁnger, 7 III ﬁnger, and 3 IV ﬁnger
right and left), 8 distal interphalangeal (5 II ﬁnger and 3 III
ﬁnger right and left), and 4 proximal interphalangeal (1 II
ﬁnger, 2 III and IV ﬁnger, and 1 V ﬁnger right and left).
Table 1: Patients demographics and disease characteristics at
baseline.
Number of patients 40
Male/female 21/19
Age, (mean ± SD) 51.5 ± 10.3
Duration of disease
Psoriasis (mean ± SD) 22.2 ± 11.5
Psoriatic arthritis (mean ± SD) 10.7 ± 7.7
PASI (mean ± SD) 9.2 ± 10.8
Pain VAS (mean ± SD) 65 ± 21.3
DAS 28 (mean ± SD) 4.6 ± 1.5
ESR (mean ± SD) 34.7 ± 21.6
CRP (mean ± SD) 20.8 ± 16.4
Age of onset (mean ± SD)
Psoriasis (mean ± SD) 29.3 ± 16.5
Psoriatic arthritis (mean ± SD) 40.8 ± 12.2
Previous methotrexate treatment 31 (77.5%)
Previous ciclosporin treatment 35 (87.5%)
Previous pUVA-UVB treatment 14 (35%)
Previous leﬂunomide treatment 17 (42.5%)
Previous sulphasalazine treatment 12 (30%)
2.1. US-PD Evaluation. US was performed with Logiq 5 Pro
(GE Healthcare, Milwaukee, USA) using a high-frequency
—12MHz—linear array transducer with power Doppler
unit. The US study was performed by an experienced
rheumatologist sonographer (X) who was blinded to the
clinical and laboratory ﬁndings in each patient. Each joint
was examined by performing both longitudinal and trans-
verse scans. In addition, power Doppler was used with the
followingsettings:PRF0.7KHzgain18–30dB,lowﬁlter.The
color box was restricted to the vascular area studied. Intra-
articular color density was quantiﬁed in the longitudinal
and transverse views within a user-deﬁned region of interest
(ROI). Using a multiplanar scanning technique, the presence
of any inﬂammation-related change in the joints and/or in
the adjacent tendon sheaths and bursae synovial eﬀusion
(SE), synovial proliferation (SP), increased local perfusion
by power Doppler) was assessed. The presence of permanent
joint damage bone erosions (BE) was also registered.
All the changes within each articular and periarticular
structurebothonB-modeandPDUSwererecordedasbeing
present in accordance with the OMERACT deﬁnitions of
Ultrasound Pathology.
PD signal intensity was graded with a scale (ranging 0–
3): grade 0: no signal; grade 1: less 1/3 of ROI; grade 2: less
2/3 of ROI; grade 3: more 2/3 of ROI on a zone of synovial
hypertrophy.
Furthermore, for all the changes in B-mode, a semiquan-
titative score (0–3) was used for each structure examined
indicating the degree of inﬂammatory activity and structural
damage (0: normal; 1: mild change; 2: moderate change; 3:
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values: grade 0: absence of erosions; grade 1: 1-2 erosions;
grade 2: >2 erosions; grade 3: large destructed area. US-PD
measures are summarized in Table 2.
2.2. Statistical Analysis. Data from the clinicolaboratory
analyses were entered into a Windows-based database
(Microsoft Excel 2007) and all statistical analyses were
performed using the statistical software GraphPad Prism 5
statistical software (GraphPad Software, San Diego, CA).
Datawereexpressedasmean ±standarddeviation(SD).The
signiﬁcance of diﬀerences in mean values obtained at T0, T4,
T12, and T24 weeks of treatment was assessed with Student’s
t-test (statistical signiﬁcance was set at P ≤ 0.05).
3. Results andDiscussion
3.1. Patient Characteristics. Forty patients (21 males and 19
females) with moderate-to-severe PsA were recruited in the
study. The mean age was 51.5 years (mean ± SD: 51.5±10.3,
range 33–76), and the duration of the disease ranged from 1
to 31 years (mean ± SD: 10.7 ±7.7).
With respect to baseline ﬁndings, at all follow-up exam-
inations (weeks 4, 12, and 24), a signiﬁcant reduction in
all clinical, laboratory, and ultrasonographic (P ≤ 0.005)
parameters of disease activity was found.
Findings on the clinical, laboratory, and US-PD parame-
ters assessed throughout the study are shown in Table 2.
3.2. Clinical Findings. The disease activity, as expressed by
the DAS28-ESR, revealed a decrease from baseline (mean
DAS28-ESR of 4.6) to T4 (mean DAS28-ESR of 4.3) and a
statistical signiﬁcant reduction at T12 (mean DAS28-ESR of
3.7) and T24 (mean DAS28-ESR of 3.6) was observed.
The PASI score showed at baseline a mean value of 9.2.
We observed a signiﬁcant improvement in mean PASI score:
f r o m4 . 6a tT 4t o1 . 8a tT 1 2a n dm a i n t a i n s1 . 8a tT 2 4 .
Patient’s clinical assessment for pain showed a statistical
s i g n i ﬁ c a n tr e d u c t i o ni nm e a np a i nV A Sv a l u e sf r o m6 5 . 0a t
T0, 50.4 at T4, 34.4 at T12, to 12.3 at T24.
The mean SpA-HAQ functional disability index revealed
a dramatical impairment from 1.1 at baseline to 0.5 at 4
w e e k sa n df r o m0 . 1a t1 2w e e k st o0 . 0a t2 4w e e k s .
No patients required additional drugs during the 24
weeks of followup.
The safety proﬁle of the drug during the treatment was
satisfactory. The most frequently complained adverse event
that was an injection site reaction observed in 7 patients
during treatment. Five patients referred a urinary tract
infection was resolved with an antimicrobial oral treatment
and did not require the discontinuation of adalimumab.
3.3. Laboratory Findings. The mean ESR decreased slowly
from baseline (value of 34.7) to T4 (value of 29.3); instead
we observed a signiﬁcant reduction of mean ESR from 20.7
at T12 to 6.8 at T24.
Likewise, the mean CRP values showed a speciﬁc trend
with just a partial reduction from 20.8 at T0 to 18.9 at T4. At





















Figure 2: Parallel decrease in US, PD, and SpA-HAQ parameters at
week 12.
3.4. US Findings. According to the data analysed for clinical
and laboratory ﬁndings, our US-PD evaluation showed
a statistical signiﬁcant improvement in all the measures
performed except for BE.
We observed that the most involved joints examined
demonstrate signs of inﬂammation at baseline: mean SE was
2.3, mean SP was 1.12, and mean PD score was of 2.5 in all
the 40 of 40 joints (100%).
A statistical signiﬁcant improvement of mean values of
SE, SP, and PD was achieved. At T4 mean SE was 1.5, mean
SP was 0.9, and mean PD was 1.8. At T12 mean SE was 0.4,
mean SP was 0.15, and mean PD was 1.1. At T24 mean SE
was 0.1, mean SP was 0.025, and PD was 1.0.
A signiﬁcant parallel decrease in SE, SP, and PD values
was demonstrated. On the contrary, no modiﬁcations on
BE measures were observed during the study as appeared in
Figure 1.
A signiﬁcant parallel decrease in US, PD, and SpA-
HAQ parameters was found at the assessment at week 12
(P<0.0005 for within-subject between-visit changes in each
parameter) as shown in Figure 2.
Representative images of US and PD changes in an MCF
joint after adalimumab treatment are shown in Figures 3 and
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Table 2: Clinicolaboratory parameters and US-cPD measures.
Baseline T4 T12 T24
ESR mean (range) 34.7 (6–79) 29.3 (5–68) 20.7 (1–76) 6.8 (2–17)
CRP mean (range) 20,8 (1.6–68.9) 18,9 (1.1–64.7) 13,1 (1.1–48.3) 5,1 (0.2–23.9)
Pain VAS mean (range) 65,0 (13–100) 50,4 (0–98) 34,4 (0–87) 12,35 (0–72)
SpA-HAQ mean (range) 1.1 (0.8–2.3) 0.5 (0.1–1) 0.1 (0–0.8) 0.0 (0–0.3)
PASI mean (range) 9.2 (0–61.8) 4.6 (0–34.5) 1.8 (0–21.2) 1.9 (0–13.9)
DAS 28-ESR mean (range) 4.6 (2.8–7.7) 4.3 (2.6–6.9) 3.7 (2.1–5.8) 2,6 (1.4–3.8)
SP mean (range) 1,125 (0–2) 0,9 (0–2) 0,15 (0-1) 0,025 (0-1)
SE mean (range) 2.3 (1–3) 1.5 (0–3) 0.4 (0–2) 0.1 (0-1)
BE mean (range) 0,2 (0–2) 0,2 (0–2) 0,2 (0–2) 0,25 (0–2)
cPD mean (range) 2.5 (1–3) 1.8 (0–3) 1.1 (0–3) 1 (0–2)
Figure 3: MCF joint with synovial eﬀusion grade 2 and cPD signal grade 3 at baseline.
4. Discussion
The development of anti-TNFα therapies, which target a
speciﬁc cytokine of the immune system, has dramatically
changed the treatment of psoriasis and psoriatic arthritis
over the last years. Tumor necrosis factor (TNFα) blockers
have been veriﬁed to be useful in the management of
many clinical disease expressions of PsA including peripheral
arthropathy, axial involvement, enthesitis, and cutaneous
manifestations [16, 17]. Considering the limited data regard-
ing the eﬃcacy of conventional therapies in preventing
radiographic progression of PsA and in ameliorating the
disability in PsA patients, adalimumab therapy represents a
signiﬁcant advance in the treatment of both skin and joints.
In fact, adalimumab monotherapy, at a dosage of 40mg
subcutaneously every other week, is an eﬀective and safe
treatment with a rapid onset of action for the management
of PsA, as conﬁrmed the data reported before [18]. As
demonstratedinseveralstudies,USandPDareabletodetect
synovial vascularization and can be considered a routinely
available, noninvasive, and relatively inexpensive bedside
imaging modality with high patient acceptability, which
allows the scanning of all peripheral joints as many times
as required in inﬂammatory joint disease [19]. Recently, the
use of power Doppler and the technological improvement
of US equipment have further shown the usefulness of this
diagnostic tool in the evaluation of arthritis [12, 20, 21].
Gutierrez et al. reported the validity, responsiveness, and
predictive value of power Doppler ultrasonography moni-
toring of response to TNFα blockers in a long-multicentric
study of 367 RA patients. Moreover, the persistence of syn-
ovial PD signal appears to have predictive value in relation to
radiological progression in patients with established RA who
are treated with anti-TNFα therapy [22].
In a longitudinal study of 20 patients made by Fiocco
et al., the eﬃcacy of etanercept in rheumatoid and psoriatic
knee joint synovitis (KJS) was determined by assessing the
time-dependent changes in disease activity and in combined
grey scale and power Doppler ultrasonographic outcome
measures [13].
Our study represents the ﬁrst attempt to investigate,
by clinical, laboratory, and US-PD evaluation, the eﬀects
of adalimumab therapy in moderate-to-severe PsA patients.
Adalimumab eﬃcacy was consistent as expressed by theClinical and Developmental Immunology 5
Figure 4: MCF joint with synovial hypertrophy grade 0 and cPD signal grade 0 at week 24.
improvement of the disease activity parameters, and the
safety proﬁle was excellent. The changes in clinical and
ultrasonographic ﬁndings were concordant in showing a
sustained reduction in disease activity indices, as DAS28-
ESR, PASI, and SpA-HAQ particularly at week 12. At this
time, the reduction in ultrasonographic measures (SP, SE,
and PD) appeared highly signiﬁcant as shown in Figure 3.
Our study suggests that US-PD is a useful and sensitive
imaging instrument for assessing the response to treatment
with adalimumab of synovitis. We have reported that the
most involved joint is suitable to be assessed by US-PD for
detecting improvements in SP and in SE induced by the
treatment. On the contrary, no changes in BE were observed,
probably for the conciseness of the study.
Actually, no clearly predictive makers of response to
biological agents are established as well as there are no spe-
ciﬁc tools to deﬁne the remission of PsA during treatment.
In this regards, US-PD changes have been shown to be
complementary to the standard clinical evaluation in joints
assessment and to provide similar proﬁles of systemic disease
activity indices in monitoring response to treatment.
5. Conclusion
Our experience, although preliminary, demonstrated in a
consistent number of PsA patients that US-PD is a valid
technique in monitoring the response to adalimumab in
moderate-to-severe PsA. Indeed, this diagnostic method
has many advantages over other procedures to analyze
clinical indices of disease activity [23]. We reported a link
between US-PD ﬁndings and the frequently used clinical
and serological indices of disease activity. This conﬁrmed
the use of US-PD as one of the options in monitoring
clinical eﬃcacy of anti-TNFα therapy in PsA [24, 25]. To
the best of our knowledge, there are no reports of sustained
regression of ultrasonographic synovial involvement after
adalimumab treatment in moderate-to-severe PsA resistant
to other synthetic DMARDs treatment. Further studies are
needed to better evaluate the role of US-PD in monitoring
the eﬃcacy of anti-TNFα treatment in PsA and to compare




TNFα: tumor necrosis factor-α
DMARDs: disease modifying anti-rheumatic drugs
CASPAR criteria: (ClASsiﬁcation criteria for Psoriatic ARthritis)
ESR: Erythrocyte sedimentation rate
CRP: C-reative protein
VAS: Visual Analogue Scale
SpA-HAQ: Health Assessment Questionnaire modiﬁed for
Spondyloarthritis
PASI: Psoriasis Area and Severity Index
DAS28-ESR: 28 joint Disease Activity Score
US: Ultrasonography
PD: power Doppler






M. Teoli and A. Zangrilli equally contribute to the paper.
Acknowledgment
The authors are grateful to Dr. Marina Papoutsaki for
critically reading the paper and for helpful suggestions.
References
[1] D. D. Gladman, P. J. Mease, C. T. Ritchlin et al., “Adalimumab
for long-term treatment of psoriatic arthritis: forty-eight week
data from the Adalimumab Eﬀectiveness in Psoriatic Arthritis
Trial,” Arthritis and Rheumatism, vol. 56, no. 2, pp. 476–488,
2007.
[2] A.J.HueberandI.B.McInnes,“Immuneregulationinpsoria-
sis and psoriatic arthritis-Recent developments,” Immunology
Letters, vol. 114, no. 2, pp. 59–65, 2007.6 Clinical and Developmental Immunology
[3] W. A. Myers, A. B. Gottlieb, and P. Mease, “Psoriasis and
psoriatic arthritis: clinical features and disease mechanisms,”
Clinics in Dermatology, vol. 24, no. 5, pp. 438–447, 2006.
[4] L. Congi and E. Roussou, “Clinical application of the CASPAR
criteria for psoriatic arthritis compared to other existing
criteria,” Clinical and experimental rheumatology, vol. 28, no.
3, pp. 304–310, 2010.
[5] P.J.Mease,“Adalimumab:ananti-TNFagentforthetreatment
of psoriatic arthritis,” Expert Opinion on Biological Therapy,
vol. 5, no. 11, pp. 1491–1504, 2005.
[6] P. J. Mease, B. S. Goﬀe ,J .M e t z ,A .V a n d e r s t o e p ,B .F i n c k ,a n d
D. J. B¨ urge, “Etanercept in the treatment of psoriatic arthritis
and psoriasis: a randomised trial,” Lancet, vol. 356, no. 9227,
pp. 385–390, 2000.
[7] P. J. Mease, “Etanercept, a TNF antagonist for treatment for
psoriatic arthritis and psoriasis,” Skin therapy letter, vol. 8, no.
1, pp. 1–4, 2003.
[8] C. E. Antoni, A. Kavanaugh, B. Kirkham et al., “Sustained
beneﬁts of inﬂiximab therapy for dermatologic and artic-
ular manifestations of psoriatic arthritis: results from the
Inﬂiximab Multinational Psoriatic Arthritis Controlled Trial
(IMPACT),” Arthritis and Rheumatism,v o l .5 2 ,n o .4 ,p p .
1227–1236, 2005.
[9] M. Papoutsaki, A. Costanzo, M. S. Chimenti, and S. Chimenti,
“Adalimumab for the treatment of severe psoriasis and
psoriatic arthritis,” Expert Opinion on Biological Therapy, vol.
8, no. 3, pp. 363–370, 2008.
[10] K. B. Gordon, R. G. Langley, C. Leonardi et al., “Clinical
response to adalimumab treatment in patients with moderate
to severe psoriasis: double-blind, randomized controlled trial
and open-label extension study,” Journal of the American
Academy of Dermatology, vol. 55, no. 4, pp. 598–606, 2006.
[ 1 1 ]M .P a p o u t s a k i ,M .S .C h i m e n t i ,A .C o s t a n z oe ta l . ,“ A d a l i -
mumab for severe psoriasis and psoriatic arthritis: an open-
label study in 30 patients previously treated with other
biologics,” Journal of the American Academy of Dermatology,
vol. 57, no. 2, pp. 269–275, 2007.
[12] A. Iagnocco, E. Filippucci, C. Perella et al., “Clinical and
ultrasonographic monitoring of response to adalimumab
treatment in rheumatoid arthritis,” Journal of Rheumatology,
vol. 35, no. 1, pp. 35–40, 2008.
[ 1 3 ] U .F i o c c o ,F .F e rr o ,M .V e z z` u et al., “Rheumatoid and psoriatic
knee synovitis: clinical, grey scale, and power Doppler ultra-
sound assessment of the response to etanercept,” Annals of the
Rheumatic Diseases, vol. 64, no. 6, pp. 899–905, 2005.
[14] H. B. Hammer, M. Sveinsson, A. K. Kongtorp, and T. K. Kvien,
“A 78-joints ultrasonographic assessment is associated with
clinical assessments and is highly responsive to improvement
in a longitudinal study of patients with rheumatoid arthritis
starting adalimumab treatment,” Annals of the Rheumatic
Diseases, vol. 69, no. 7, pp. 1349–1351, 2010.
[15] R. J. Wakeﬁeld, P. V. Balint, M. Szkudlarek et al., “Mus-
culoskeletal ultrasound including deﬁnitions for ultrasono-
graphic pathology,” Journal of Rheumatology, vol. 32, no. 12,
pp. 2485–2487, 2005.
[16] P. Tristani-Firouzi and G. G. Krueger, “Eﬃcacy and safety of
treatment modalities for psoriasis,” Cutis,v o l .6 1 ,n o .2 ,p p .
11–21, 1998.
[17] L. Punzi, M. Podswiadek, P. Sfriso, F. Oliviero, U. Fiocco,
and S. Todesco, “Pathogenetic and clinical rationale for
TNF-blocking therapy in psoriatic arthritis,” Autoimmunity
Reviews, vol. 6, no. 8, pp. 524–528, 2007.
[18] N. Scheinfeld, “Adalimumab: a review of side eﬀects,” Expert
Opinion on Drug Safety, vol. 4, no. 4, pp. 637–641, 2005.
[19] A. Delle Sedie, L. Riente, E. Filippucci et al., “Ultrasound
imaging for the rheumatologist XXVI. Sonographic assess-
ment of the knee in patients with psoriatic arthritis,” Clinical
and Experimental Rheumatology, vol. 28, no. 2, pp. 147–152,
2010.
[20] M. Walther, H. Harms, V. Krenn, S. Radke, T. P. Faehndrich,
and F. Gohlke, “Correlation of power Doppler sonography
with vascularity of the synovial tissue of the knee joint
in patients with osteoarthritis and rheumatoid arthritis,”
Arthritis and Rheumatism, vol. 44, no. 2, pp. 331–338, 2001.
[21] A. Delle Sedie, L. Riente, E. Filippucci et al., “Ultrasound
imaging for the rheumatologist xxxii. sonographic assessment
of the foot in patients with psoriatic arthritis,” Clinical and
Experimental Rheumatology, vol. 29, no. 2, pp. 217–222, 2011.
[22] M. Gutierrez, E. Filippucci, F. Salaﬃ, L. Di Geso, and W.
Grassi, “Diﬀerential diagnosis between rheumatoid arthritis
and psoriatic arthritis: the value of ultrasound ﬁndings at
metacarpophalangeal joints level,” Annals of the Rheumatic
Diseases, vol. 70, no. 6, pp. 1111–1114, 2011.
[23] E. Filippucci, A. Iagnocco, F. Salaﬃ, A. Cerioni, G. Valesini,
and W. Grassi, “Power Doppler sonography monitoring
of synovial perfusion at the wrist joints in patients with
rheumatoid arthritis treated with adalimumab,” Annals of the
Rheumatic Diseases, vol. 65, no. 11, pp. 1433–1437, 2006.
[24] K. Albrecht, K. Grob, U. Lange, U. M¨ uller-ladner, and J.
Strunk, “Reliability of diﬀerent Doppler ultrasound quantiﬁ-
cation methods and devices in the assessment of therapeutic
response in arthritis,” Rheumatology, vol. 47, no. 10, pp. 1521–
1526, 2008.
[25] D. D. Gladman, V. T. Farewell, and C. Nadeau, “Clinical
indicators of progression in psoriatic arthritis: multivariate
relative risk model,” Journal of Rheumatology, vol. 22, no. 4,
pp. 675–679, 1995.